Jie Bi Network news reports that, according to a Chainalysis report, gray-market peptide drug suppliers have turned to using Bitcoin and stablecoins due to traditional payment restrictions. In the first quarter of 2026, related crypto funds inflows reached $32 million, up 159% from $12 million in the previous quarter, with an annualized scale exceeding $100 million. The report says demand for peptide products is driven by medical aesthetics and health trends, and some leading suppliers have adopted more professional on-chain fund management; the proportion of stablecoins in large transactions has increased significantly to reduce the risk of market volatility.

BTC-0.23%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 4
  • 2
  • Share
Comment
Add a comment
Add a comment
TakeAScreenshotBefore
· 3h ago
Large transfers to stablecoins reduce volatility; suppliers understand risk control better than retail investors.
View OriginalReply0
IOnlyTrustOn-ChainData.
· 10h ago
On-chain capital flow driven by aesthetic medical demand, regulators find it troublesome to oversee
View OriginalReply0
AirdropMileCounter
· 10h ago
Annualized 100 million dollars, this track is more stable than some legit DeFi protocols.
View OriginalReply0
GateUser-739338fe
· 10h ago
The gray market has already moved to stablecoins, while compliant payments are still dragging their feet.
View OriginalReply0
  • Pinned